Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 2 | 54 | 2024 | 2087 | 5.850 |
Why?
|
Cardiovascular Diseases | 26 | 2024 | 1726 | 3.790 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 30 | 2014 | 126 | 3.160 |
Why?
|
Muscle, Smooth, Vascular | 14 | 2016 | 409 | 2.890 |
Why?
|
Hypoglycemic Agents | 23 | 2023 | 1011 | 2.570 |
Why?
|
Mitochondria, Muscle | 8 | 2021 | 92 | 2.470 |
Why?
|
Insulin Resistance | 29 | 2024 | 1072 | 2.320 |
Why?
|
Diabetes Mellitus | 11 | 2023 | 898 | 2.110 |
Why?
|
Mitochondria | 11 | 2022 | 744 | 1.910 |
Why?
|
Endothelium, Vascular | 12 | 2022 | 830 | 1.780 |
Why?
|
Blood Vessels | 5 | 2018 | 179 | 1.750 |
Why?
|
Insulin | 27 | 2023 | 2080 | 1.680 |
Why?
|
Diabetic Angiopathies | 10 | 2017 | 246 | 1.570 |
Why?
|
Exercise | 22 | 2022 | 1642 | 1.540 |
Why?
|
Aorta | 9 | 2018 | 388 | 1.530 |
Why?
|
Microcirculation | 7 | 2018 | 133 | 1.490 |
Why?
|
Metformin | 6 | 2022 | 274 | 1.480 |
Why?
|
Exercise Tolerance | 9 | 2024 | 212 | 1.410 |
Why?
|
Microvessels | 4 | 2018 | 66 | 1.370 |
Why?
|
Adaptation, Physiological | 6 | 2021 | 484 | 1.350 |
Why?
|
Thiazolidinediones | 11 | 2021 | 142 | 1.300 |
Why?
|
Myocytes, Smooth Muscle | 6 | 2016 | 236 | 1.290 |
Why?
|
Muscle, Skeletal | 17 | 2023 | 1468 | 1.220 |
Why?
|
Diabetes Mellitus, Type 1 | 19 | 2022 | 3254 | 1.220 |
Why?
|
Glucose | 13 | 2022 | 899 | 1.180 |
Why?
|
Metabolic Syndrome | 9 | 2019 | 320 | 1.130 |
Why?
|
Models, Cardiovascular | 3 | 2017 | 179 | 1.130 |
Why?
|
Vascular Stiffness | 5 | 2023 | 410 | 1.110 |
Why?
|
Blood Glucose | 21 | 2024 | 1827 | 1.090 |
Why?
|
Hyperglycemia | 4 | 2017 | 292 | 1.080 |
Why?
|
Rats | 36 | 2023 | 4913 | 1.080 |
Why?
|
Catechin | 3 | 2022 | 23 | 1.080 |
Why?
|
Oxidative Stress | 11 | 2022 | 1068 | 1.030 |
Why?
|
Obesity | 17 | 2023 | 2505 | 1.020 |
Why?
|
Oxygen Consumption | 18 | 2021 | 587 | 1.000 |
Why?
|
Diabetic Neuropathies | 2 | 2023 | 78 | 0.990 |
Why?
|
Glucose Intolerance | 2 | 2024 | 137 | 0.990 |
Why?
|
Nitric Oxide Synthase Type III | 6 | 2020 | 181 | 0.950 |
Why?
|
Glucagon-Like Peptide 1 | 6 | 2020 | 100 | 0.950 |
Why?
|
Oxygen | 3 | 2018 | 851 | 0.940 |
Why?
|
Hypertension | 5 | 2022 | 1052 | 0.900 |
Why?
|
Glucagon-Like Peptide-1 Receptor | 5 | 2021 | 73 | 0.860 |
Why?
|
Oxidative Phosphorylation | 5 | 2021 | 154 | 0.860 |
Why?
|
Humans | 118 | 2024 | 114045 | 0.840 |
Why?
|
Sex Factors | 7 | 2022 | 1706 | 0.810 |
Why?
|
Drug Design | 1 | 2023 | 147 | 0.810 |
Why?
|
Vascular Diseases | 2 | 2022 | 233 | 0.800 |
Why?
|
Cardiorespiratory Fitness | 3 | 2019 | 35 | 0.790 |
Why?
|
Insulins | 1 | 2022 | 32 | 0.780 |
Why?
|
Animals | 66 | 2023 | 31565 | 0.750 |
Why?
|
Rats, Wistar | 6 | 2023 | 368 | 0.690 |
Why?
|
Diabetes Mellitus, Experimental | 3 | 2016 | 160 | 0.690 |
Why?
|
Physical Conditioning, Animal | 3 | 2018 | 194 | 0.680 |
Why?
|
Cardiovascular System | 3 | 2024 | 126 | 0.680 |
Why?
|
Blood Flow Velocity | 6 | 2018 | 388 | 0.660 |
Why?
|
Human Umbilical Vein Endothelial Cells | 2 | 2020 | 88 | 0.660 |
Why?
|
Motor Activity | 3 | 2015 | 635 | 0.660 |
Why?
|
Fatty Acids, Nonesterified | 6 | 2016 | 150 | 0.640 |
Why?
|
Pterins | 1 | 2018 | 8 | 0.620 |
Why?
|
Male | 61 | 2023 | 55396 | 0.600 |
Why?
|
Leadership | 1 | 2021 | 291 | 0.600 |
Why?
|
Adipocytes | 7 | 2001 | 188 | 0.600 |
Why?
|
Vasodilation | 7 | 2022 | 418 | 0.580 |
Why?
|
Sex Characteristics | 9 | 2023 | 636 | 0.580 |
Why?
|
Women's Health | 3 | 2020 | 270 | 0.570 |
Why?
|
Atherosclerosis | 3 | 2011 | 342 | 0.550 |
Why?
|
Cell Division | 7 | 2009 | 754 | 0.550 |
Why?
|
Arterioles | 2 | 2016 | 39 | 0.550 |
Why?
|
Carotid Arteries | 1 | 2018 | 180 | 0.550 |
Why?
|
Metabolomics | 2 | 2020 | 511 | 0.550 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 4 | 2021 | 43 | 0.540 |
Why?
|
Nitric Oxide | 3 | 2022 | 817 | 0.530 |
Why?
|
Hemorheology | 1 | 2016 | 20 | 0.530 |
Why?
|
Glycocalyx | 1 | 2016 | 18 | 0.520 |
Why?
|
Models, Biological | 4 | 2020 | 1611 | 0.520 |
Why?
|
Diabetes Complications | 2 | 2020 | 208 | 0.510 |
Why?
|
Capillaries | 1 | 2016 | 90 | 0.510 |
Why?
|
Needs Assessment | 1 | 2018 | 315 | 0.510 |
Why?
|
Female | 59 | 2023 | 59324 | 0.510 |
Why?
|
Software | 2 | 2018 | 526 | 0.500 |
Why?
|
Risk Factors | 16 | 2022 | 8614 | 0.490 |
Why?
|
Adamantane | 1 | 2015 | 15 | 0.480 |
Why?
|
Cell Respiration | 3 | 2020 | 71 | 0.480 |
Why?
|
Dipeptides | 1 | 2015 | 47 | 0.480 |
Why?
|
Adipose Tissue | 6 | 2021 | 545 | 0.450 |
Why?
|
Regional Blood Flow | 7 | 2020 | 421 | 0.450 |
Why?
|
Diabetic Cardiomyopathies | 4 | 2020 | 34 | 0.430 |
Why?
|
Biomedical Research | 2 | 2018 | 582 | 0.430 |
Why?
|
Mitochondrial Dynamics | 1 | 2013 | 22 | 0.420 |
Why?
|
Disease Models, Animal | 8 | 2018 | 3498 | 0.420 |
Why?
|
Overweight | 3 | 2023 | 473 | 0.420 |
Why?
|
Adolescent | 26 | 2023 | 17800 | 0.390 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 5 | 2005 | 211 | 0.390 |
Why?
|
Patient-Centered Care | 1 | 2017 | 470 | 0.390 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2015 | 684 | 0.380 |
Why?
|
Tetrazoles | 1 | 2011 | 32 | 0.380 |
Why?
|
Phosphodiesterase 3 Inhibitors | 1 | 2011 | 13 | 0.380 |
Why?
|
Glucose Tolerance Test | 3 | 2024 | 343 | 0.370 |
Why?
|
Hyperinsulinism | 5 | 2019 | 103 | 0.370 |
Why?
|
Signal Transduction | 8 | 2022 | 4501 | 0.370 |
Why?
|
Endothelial Cells | 1 | 2016 | 677 | 0.370 |
Why?
|
Pulse Wave Analysis | 5 | 2023 | 207 | 0.360 |
Why?
|
Phosphorylation | 16 | 2013 | 1558 | 0.360 |
Why?
|
Exercise Therapy | 3 | 2022 | 351 | 0.350 |
Why?
|
Proto-Oncogene Proteins | 4 | 2009 | 607 | 0.350 |
Why?
|
Cell Nucleus | 6 | 2016 | 552 | 0.350 |
Why?
|
Promoter Regions, Genetic | 5 | 2003 | 1131 | 0.350 |
Why?
|
Cell Movement | 4 | 2011 | 863 | 0.340 |
Why?
|
Hypoglycemia | 1 | 2014 | 386 | 0.340 |
Why?
|
Aging | 2 | 2018 | 1611 | 0.340 |
Why?
|
Hyperlipidemias | 3 | 2017 | 121 | 0.330 |
Why?
|
Rats, Sprague-Dawley | 9 | 2013 | 2182 | 0.330 |
Why?
|
Lipoproteins, LDL | 1 | 2010 | 127 | 0.330 |
Why?
|
Mentoring | 2 | 2022 | 99 | 0.330 |
Why?
|
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 3 | 2021 | 40 | 0.320 |
Why?
|
Trans-Activators | 2 | 2001 | 366 | 0.320 |
Why?
|
Pulmonary Artery | 6 | 2013 | 1024 | 0.320 |
Why?
|
Sirtuin 3 | 2 | 2020 | 51 | 0.320 |
Why?
|
Insulin-Like Growth Factor I | 3 | 2000 | 286 | 0.310 |
Why?
|
Cells, Cultured | 14 | 2011 | 3861 | 0.310 |
Why?
|
Ventricular Dysfunction, Left | 3 | 2020 | 371 | 0.290 |
Why?
|
Superoxides | 2 | 2020 | 190 | 0.290 |
Why?
|
Hemodynamics | 3 | 2021 | 1015 | 0.290 |
Why?
|
Leg | 2 | 2021 | 224 | 0.290 |
Why?
|
Adult | 26 | 2022 | 30375 | 0.280 |
Why?
|
Vasoconstriction | 2 | 2018 | 177 | 0.280 |
Why?
|
Nuclear Proteins | 2 | 2001 | 591 | 0.280 |
Why?
|
Drug Therapy, Combination | 3 | 2021 | 949 | 0.280 |
Why?
|
Cell Differentiation | 4 | 2004 | 1696 | 0.280 |
Why?
|
Citrate (si)-Synthase | 3 | 2021 | 45 | 0.280 |
Why?
|
Echocardiography | 4 | 2020 | 569 | 0.270 |
Why?
|
Receptor, Insulin | 3 | 1996 | 93 | 0.270 |
Why?
|
Arteriosclerosis | 2 | 2003 | 82 | 0.270 |
Why?
|
Sulfonylurea Compounds | 3 | 2021 | 44 | 0.260 |
Why?
|
Biomarkers | 6 | 2023 | 3397 | 0.260 |
Why?
|
Peptide Fragments | 3 | 2021 | 665 | 0.260 |
Why?
|
Incretins | 2 | 2017 | 15 | 0.260 |
Why?
|
Glycation End Products, Advanced | 1 | 2006 | 57 | 0.260 |
Why?
|
Mitogen-Activated Protein Kinases | 4 | 2009 | 269 | 0.250 |
Why?
|
Down-Regulation | 2 | 2010 | 594 | 0.250 |
Why?
|
Myocardial Contraction | 2 | 2020 | 318 | 0.250 |
Why?
|
Pediatric Obesity | 3 | 2017 | 489 | 0.250 |
Why?
|
Reactive Oxygen Species | 2 | 2022 | 522 | 0.240 |
Why?
|
Kinetics | 9 | 2017 | 1547 | 0.240 |
Why?
|
Diabetic Nephropathies | 2 | 2020 | 234 | 0.240 |
Why?
|
Ventricular Function, Left | 2 | 2020 | 477 | 0.240 |
Why?
|
Monosaccharide Transport Proteins | 4 | 2001 | 45 | 0.240 |
Why?
|
Lipids | 4 | 2022 | 564 | 0.240 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 1 | 2004 | 34 | 0.230 |
Why?
|
Time Management | 1 | 2004 | 18 | 0.230 |
Why?
|
Middle Aged | 19 | 2020 | 26605 | 0.230 |
Why?
|
Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2003 | 14 | 0.220 |
Why?
|
Case-Control Studies | 6 | 2023 | 3003 | 0.220 |
Why?
|
Double-Blind Method | 6 | 2019 | 1656 | 0.220 |
Why?
|
Coronary Disease | 2 | 2003 | 348 | 0.220 |
Why?
|
Intermediate Filaments | 1 | 2023 | 46 | 0.220 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2003 | 87 | 0.220 |
Why?
|
Neurofilament Proteins | 1 | 2023 | 34 | 0.210 |
Why?
|
Proto-Oncogene Proteins c-akt | 6 | 2013 | 397 | 0.210 |
Why?
|
Brachial Artery | 3 | 2019 | 176 | 0.200 |
Why?
|
Epidemics | 1 | 2023 | 66 | 0.200 |
Why?
|
Young Adult | 13 | 2021 | 10444 | 0.200 |
Why?
|
Transcription Factors | 6 | 2012 | 1526 | 0.200 |
Why?
|
Diastole | 2 | 2020 | 137 | 0.200 |
Why?
|
Physical Fitness | 3 | 2013 | 180 | 0.200 |
Why?
|
Autophagy | 2 | 2016 | 235 | 0.200 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2002 | 40 | 0.200 |
Why?
|
Sitagliptin Phosphate | 2 | 2019 | 30 | 0.200 |
Why?
|
Ecdysterone | 1 | 2001 | 3 | 0.200 |
Why?
|
Mitochondrial Proteins | 2 | 2015 | 213 | 0.190 |
Why?
|
Overnutrition | 1 | 2022 | 30 | 0.190 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 4 | 2001 | 228 | 0.190 |
Why?
|
Nitric Oxide Synthase | 1 | 2022 | 209 | 0.190 |
Why?
|
Faculty, Medical | 1 | 2004 | 226 | 0.190 |
Why?
|
Cattle | 4 | 2009 | 918 | 0.190 |
Why?
|
Exercise Test | 7 | 2016 | 547 | 0.190 |
Why?
|
Academic Medical Centers | 1 | 2004 | 405 | 0.190 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2021 | 64 | 0.190 |
Why?
|
Age Factors | 3 | 2021 | 2885 | 0.190 |
Why?
|
Triglycerides | 4 | 2013 | 467 | 0.180 |
Why?
|
Muscle Contraction | 3 | 2017 | 388 | 0.180 |
Why?
|
Glutathione | 1 | 2022 | 293 | 0.180 |
Why?
|
Comorbidity | 3 | 2021 | 1447 | 0.180 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 170 | 0.180 |
Why?
|
Aorta, Thoracic | 1 | 2023 | 257 | 0.180 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2021 | 138 | 0.180 |
Why?
|
Protein Kinases | 2 | 2020 | 304 | 0.180 |
Why?
|
Glycopeptides | 1 | 2021 | 43 | 0.180 |
Why?
|
Antimycin A | 1 | 2020 | 13 | 0.180 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2021 | 94 | 0.180 |
Why?
|
Clinical Trials as Topic | 2 | 2022 | 926 | 0.180 |
Why?
|
Mice | 18 | 2022 | 14843 | 0.170 |
Why?
|
Body Mass Index | 6 | 2018 | 1957 | 0.170 |
Why?
|
Electron Transport Complex I | 1 | 2020 | 33 | 0.170 |
Why?
|
Thrombosis | 2 | 2002 | 295 | 0.170 |
Why?
|
Congresses as Topic | 2 | 2020 | 193 | 0.170 |
Why?
|
Apoptosis | 3 | 2007 | 2349 | 0.170 |
Why?
|
Thiazoles | 2 | 2002 | 110 | 0.170 |
Why?
|
Thinness | 3 | 2021 | 87 | 0.170 |
Why?
|
Aged | 14 | 2022 | 18969 | 0.170 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 4 | 2010 | 249 | 0.170 |
Why?
|
Fibroblasts | 4 | 2016 | 834 | 0.170 |
Why?
|
Genes, bcl-2 | 1 | 1999 | 20 | 0.170 |
Why?
|
Perfusion | 2 | 2018 | 147 | 0.170 |
Why?
|
Cell Line | 8 | 2016 | 2629 | 0.170 |
Why?
|
Animal Nutritional Physiological Phenomena | 1 | 1999 | 12 | 0.170 |
Why?
|
Microscopy, Fluorescence | 3 | 2018 | 393 | 0.170 |
Why?
|
Inservice Training | 1 | 2020 | 106 | 0.160 |
Why?
|
Transfection | 6 | 2007 | 863 | 0.160 |
Why?
|
Oxidation-Reduction | 3 | 2020 | 917 | 0.160 |
Why?
|
Life Style | 1 | 2021 | 428 | 0.160 |
Why?
|
Treatment Outcome | 7 | 2022 | 9049 | 0.160 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 1381 | 0.160 |
Why?
|
PPAR gamma | 3 | 2022 | 182 | 0.160 |
Why?
|
Heart Diseases | 1 | 2022 | 329 | 0.160 |
Why?
|
Voltage-Dependent Anion Channel 1 | 2 | 2021 | 9 | 0.160 |
Why?
|
Deoxyglucose | 3 | 1993 | 43 | 0.150 |
Why?
|
Mentors | 1 | 2020 | 155 | 0.150 |
Why?
|
Echocardiography, Doppler | 3 | 2016 | 95 | 0.150 |
Why?
|
Microscopy, Video | 1 | 2018 | 26 | 0.150 |
Why?
|
Homocysteine | 1 | 2019 | 137 | 0.150 |
Why?
|
Carbohydrates | 1 | 2018 | 55 | 0.150 |
Why?
|
Weight Gain | 1 | 2021 | 453 | 0.150 |
Why?
|
Venoms | 2 | 2016 | 30 | 0.150 |
Why?
|
Hemoglobins | 3 | 2017 | 308 | 0.150 |
Why?
|
Bicycling | 2 | 2017 | 86 | 0.150 |
Why?
|
Platelet-Derived Growth Factor | 2 | 2010 | 80 | 0.150 |
Why?
|
Automation | 1 | 2018 | 74 | 0.150 |
Why?
|
DNA-Binding Proteins | 2 | 1995 | 1311 | 0.150 |
Why?
|
Interprofessional Relations | 1 | 2020 | 246 | 0.150 |
Why?
|
Cardiotonic Agents | 1 | 2018 | 121 | 0.150 |
Why?
|
Mitochondria, Heart | 1 | 2018 | 72 | 0.150 |
Why?
|
Cysteine | 1 | 2019 | 171 | 0.150 |
Why?
|
Glucose Clamp Technique | 4 | 2016 | 181 | 0.150 |
Why?
|
Superoxide Dismutase | 3 | 2021 | 305 | 0.150 |
Why?
|
Convection | 1 | 2017 | 7 | 0.150 |
Why?
|
Serine | 5 | 2021 | 125 | 0.150 |
Why?
|
United States | 9 | 2022 | 12137 | 0.140 |
Why?
|
Dietary Fats | 3 | 2023 | 287 | 0.140 |
Why?
|
Capillary Resistance | 1 | 2017 | 5 | 0.140 |
Why?
|
Combined Modality Therapy | 2 | 2017 | 1117 | 0.140 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2018 | 105 | 0.140 |
Why?
|
Blood Pressure | 6 | 2021 | 1531 | 0.140 |
Why?
|
Inflammasomes | 1 | 2018 | 115 | 0.140 |
Why?
|
Oxyhemoglobins | 1 | 2017 | 20 | 0.140 |
Why?
|
Incidence | 2 | 2023 | 2314 | 0.140 |
Why?
|
Phosphatidylinositol 3-Kinases | 5 | 2023 | 328 | 0.140 |
Why?
|
Heart Failure | 1 | 2010 | 1958 | 0.140 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 2 | 2010 | 157 | 0.140 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 239 | 0.140 |
Why?
|
Diffusion | 1 | 2017 | 119 | 0.140 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2017 | 47 | 0.140 |
Why?
|
Albuminuria | 2 | 2020 | 164 | 0.140 |
Why?
|
Ventricular Fibrillation | 1 | 2017 | 51 | 0.140 |
Why?
|
Neoplasm Proteins | 1 | 2000 | 385 | 0.140 |
Why?
|
Hypoxia | 4 | 2013 | 956 | 0.140 |
Why?
|
Healthy Lifestyle | 1 | 2017 | 30 | 0.140 |
Why?
|
Leptin | 2 | 2017 | 210 | 0.140 |
Why?
|
Fetal Growth Retardation | 1 | 2021 | 470 | 0.140 |
Why?
|
Disease | 1 | 2017 | 85 | 0.130 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2022 | 453 | 0.130 |
Why?
|
Adiponectin | 2 | 2016 | 213 | 0.130 |
Why?
|
Blood Viscosity | 1 | 2016 | 14 | 0.130 |
Why?
|
Kidney | 4 | 2021 | 1182 | 0.130 |
Why?
|
Pregnancy | 5 | 2022 | 5499 | 0.130 |
Why?
|
Protein Kinase Inhibitors | 2 | 2013 | 784 | 0.130 |
Why?
|
MAP Kinase Signaling System | 4 | 2013 | 271 | 0.130 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2021 | 486 | 0.130 |
Why?
|
Recombinant Fusion Proteins | 6 | 2016 | 613 | 0.130 |
Why?
|
Swine, Miniature | 2 | 2013 | 70 | 0.130 |
Why?
|
Prospective Studies | 4 | 2022 | 6195 | 0.130 |
Why?
|
Luteinizing Hormone | 1 | 2017 | 169 | 0.130 |
Why?
|
Nerve Tissue Proteins | 1 | 2000 | 527 | 0.130 |
Why?
|
Electron Transport Complex IV | 1 | 2016 | 53 | 0.130 |
Why?
|
Immediate-Early Proteins | 1 | 2016 | 52 | 0.130 |
Why?
|
Menopause | 1 | 2019 | 271 | 0.130 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2016 | 474 | 0.130 |
Why?
|
Quality of Life | 2 | 2021 | 2343 | 0.130 |
Why?
|
Follicle Stimulating Hormone | 1 | 2017 | 216 | 0.130 |
Why?
|
Vascular Resistance | 1 | 2017 | 340 | 0.130 |
Why?
|
Forearm | 2 | 2015 | 112 | 0.130 |
Why?
|
Cost of Illness | 1 | 2018 | 254 | 0.130 |
Why?
|
Goals | 1 | 2017 | 145 | 0.130 |
Why?
|
Chromans | 1 | 1995 | 21 | 0.130 |
Why?
|
Islets of Langerhans | 4 | 2007 | 728 | 0.130 |
Why?
|
Viral Envelope Proteins | 1 | 2016 | 73 | 0.130 |
Why?
|
AMP-Activated Protein Kinases | 2 | 2017 | 170 | 0.130 |
Why?
|
Capillary Permeability | 1 | 2016 | 137 | 0.130 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2016 | 70 | 0.130 |
Why?
|
PC12 Cells | 3 | 2000 | 37 | 0.130 |
Why?
|
Insulin-Secreting Cells | 1 | 2019 | 317 | 0.130 |
Why?
|
Adiposity | 2 | 2017 | 458 | 0.120 |
Why?
|
Genes, Reporter | 4 | 2016 | 256 | 0.120 |
Why?
|
Biological Assay | 1 | 2016 | 112 | 0.120 |
Why?
|
Phosphates | 2 | 1993 | 155 | 0.120 |
Why?
|
Swine | 4 | 2017 | 687 | 0.120 |
Why?
|
Drug Administration Schedule | 3 | 2014 | 714 | 0.120 |
Why?
|
Phosphoprotein Phosphatases | 1 | 1995 | 64 | 0.120 |
Why?
|
Neurons | 1 | 2003 | 1277 | 0.120 |
Why?
|
Organelle Biogenesis | 1 | 2015 | 14 | 0.120 |
Why?
|
Myocardium | 1 | 2020 | 911 | 0.120 |
Why?
|
Sleep | 1 | 2020 | 631 | 0.120 |
Why?
|
Child | 10 | 2021 | 18401 | 0.120 |
Why?
|
Hyperandrogenism | 1 | 2015 | 14 | 0.120 |
Why?
|
Mice, Knockout | 3 | 2018 | 2562 | 0.120 |
Why?
|
Body Composition | 5 | 2014 | 590 | 0.120 |
Why?
|
Ventricular Function | 1 | 2015 | 57 | 0.120 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 1994 | 54 | 0.120 |
Why?
|
Cell Survival | 4 | 2009 | 1014 | 0.120 |
Why?
|
American Heart Association | 1 | 2015 | 264 | 0.120 |
Why?
|
Magnetic Resonance Imaging | 3 | 2020 | 3039 | 0.120 |
Why?
|
Endothelium | 1 | 2015 | 109 | 0.110 |
Why?
|
Cholesterol, LDL | 3 | 2014 | 307 | 0.110 |
Why?
|
Myocytes, Cardiac | 2 | 2009 | 449 | 0.110 |
Why?
|
Healthy Volunteers | 1 | 2015 | 191 | 0.110 |
Why?
|
CREB-Binding Protein | 3 | 2006 | 27 | 0.110 |
Why?
|
Cyclic AMP | 3 | 2006 | 225 | 0.110 |
Why?
|
Retrospective Studies | 4 | 2022 | 12521 | 0.110 |
Why?
|
Models, Theoretical | 1 | 2017 | 513 | 0.110 |
Why?
|
Host-Pathogen Interactions | 1 | 2016 | 295 | 0.110 |
Why?
|
Free Radical Scavengers | 2 | 2011 | 78 | 0.110 |
Why?
|
Prevalence | 1 | 2019 | 2247 | 0.110 |
Why?
|
Electron Transport Chain Complex Proteins | 1 | 2013 | 18 | 0.110 |
Why?
|
NG-Nitroarginine Methyl Ester | 1 | 2013 | 38 | 0.110 |
Why?
|
Reaction Time | 1 | 2015 | 373 | 0.110 |
Why?
|
Blotting, Western | 6 | 2011 | 1143 | 0.110 |
Why?
|
rho-Associated Kinases | 1 | 2013 | 80 | 0.110 |
Why?
|
Peptides | 2 | 2016 | 847 | 0.110 |
Why?
|
Disease Management | 1 | 2017 | 556 | 0.110 |
Why?
|
Uncoupling Protein 3 | 1 | 2012 | 8 | 0.100 |
Why?
|
Hypertension, Pulmonary | 4 | 2013 | 1736 | 0.100 |
Why?
|
Rats, Mutant Strains | 1 | 2012 | 24 | 0.100 |
Why?
|
Rats, Inbred SHR | 2 | 2010 | 41 | 0.100 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2015 | 141 | 0.100 |
Why?
|
Cytokines | 3 | 2012 | 1824 | 0.100 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2009 | 1128 | 0.100 |
Why?
|
Herpesvirus 3, Human | 1 | 2016 | 377 | 0.100 |
Why?
|
Myocardial Reperfusion Injury | 1 | 2013 | 95 | 0.100 |
Why?
|
Heterozygote | 1 | 2013 | 250 | 0.100 |
Why?
|
Ion Channels | 1 | 2012 | 121 | 0.100 |
Why?
|
Enzyme Activation | 4 | 2010 | 771 | 0.100 |
Why?
|
Lymphocytosis | 1 | 1992 | 9 | 0.100 |
Why?
|
Hydrogen Peroxide | 2 | 2011 | 288 | 0.100 |
Why?
|
Pituitary Diseases | 1 | 1992 | 21 | 0.100 |
Why?
|
Gene Expression Regulation | 4 | 2016 | 2322 | 0.100 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 2 | 2010 | 145 | 0.100 |
Why?
|
3T3 Cells | 4 | 2000 | 140 | 0.090 |
Why?
|
Erythrocytes | 1 | 2016 | 568 | 0.090 |
Why?
|
Gene Deletion | 1 | 2013 | 356 | 0.090 |
Why?
|
Rats, Inbred WKY | 4 | 2013 | 32 | 0.090 |
Why?
|
Fatty Acids | 2 | 2018 | 380 | 0.090 |
Why?
|
Anticholesteremic Agents | 1 | 2012 | 129 | 0.090 |
Why?
|
Mitogens | 2 | 2009 | 58 | 0.090 |
Why?
|
Vitamin D | 1 | 2013 | 340 | 0.090 |
Why?
|
Cross-Sectional Studies | 5 | 2015 | 4402 | 0.090 |
Why?
|
Longevity | 2 | 2022 | 136 | 0.090 |
Why?
|
Casein Kinase II | 1 | 2010 | 21 | 0.090 |
Why?
|
Hypertrophy, Left Ventricular | 2 | 2009 | 102 | 0.090 |
Why?
|
Placebos | 3 | 2019 | 197 | 0.090 |
Why?
|
Diabetes, Gestational | 1 | 2014 | 281 | 0.090 |
Why?
|
Receptors, LDL | 1 | 2010 | 38 | 0.090 |
Why?
|
Dexamethasone | 1 | 1992 | 316 | 0.080 |
Why?
|
Uracil | 1 | 2009 | 28 | 0.080 |
Why?
|
RNA-Binding Proteins | 1 | 2012 | 344 | 0.080 |
Why?
|
Sterol Regulatory Element Binding Protein 1 | 2 | 2007 | 54 | 0.080 |
Why?
|
Calcium | 2 | 1993 | 1089 | 0.080 |
Why?
|
RNA, Messenger | 4 | 2006 | 2550 | 0.080 |
Why?
|
Receptors, Glucagon | 1 | 2009 | 23 | 0.080 |
Why?
|
Antihypertensive Agents | 1 | 2012 | 428 | 0.080 |
Why?
|
Transcription, Genetic | 4 | 2009 | 1310 | 0.080 |
Why?
|
Oncogene Proteins | 1 | 2009 | 53 | 0.080 |
Why?
|
Cardiac Output, Low | 1 | 2009 | 64 | 0.080 |
Why?
|
Diet | 4 | 2019 | 1080 | 0.080 |
Why?
|
Autoimmune Diseases | 1 | 1992 | 381 | 0.080 |
Why?
|
Mice, Inbred C57BL | 3 | 2021 | 4680 | 0.080 |
Why?
|
Physical Exertion | 1 | 2009 | 209 | 0.080 |
Why?
|
Heart | 2 | 2024 | 613 | 0.080 |
Why?
|
Piperidines | 1 | 2009 | 159 | 0.080 |
Why?
|
Time Factors | 3 | 2014 | 6077 | 0.070 |
Why?
|
C-Reactive Protein | 2 | 2009 | 362 | 0.070 |
Why?
|
Gene Expression | 1 | 2013 | 1417 | 0.070 |
Why?
|
Physical Endurance | 1 | 2009 | 232 | 0.070 |
Why?
|
Genes, Dominant | 2 | 2007 | 93 | 0.070 |
Why?
|
Enzyme Inhibitors | 3 | 2013 | 743 | 0.070 |
Why?
|
Pregnancy Complications | 1 | 1992 | 430 | 0.070 |
Why?
|
HIV Infections | 1 | 2021 | 2453 | 0.070 |
Why?
|
Brain | 1 | 2018 | 2355 | 0.070 |
Why?
|
Sequence Deletion | 2 | 1999 | 166 | 0.070 |
Why?
|
Disease Progression | 2 | 2019 | 2371 | 0.070 |
Why?
|
Vasodilator Agents | 2 | 2013 | 302 | 0.070 |
Why?
|
Perception | 1 | 2009 | 309 | 0.070 |
Why?
|
Luciferases | 3 | 2005 | 142 | 0.070 |
Why?
|
Cholesterol | 2 | 2013 | 368 | 0.070 |
Why?
|
Fibrinolysis | 3 | 2003 | 126 | 0.070 |
Why?
|
Sports | 1 | 2009 | 187 | 0.070 |
Why?
|
In Vitro Techniques | 2 | 2001 | 1003 | 0.070 |
Why?
|
Cell Proliferation | 5 | 2013 | 2173 | 0.070 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2009 | 388 | 0.070 |
Why?
|
Creatinine | 2 | 2020 | 424 | 0.070 |
Why?
|
Receptor for Advanced Glycation End Products | 1 | 2006 | 29 | 0.070 |
Why?
|
Oxidants | 2 | 2005 | 112 | 0.070 |
Why?
|
Food Deprivation | 1 | 2006 | 24 | 0.060 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2006 | 133 | 0.060 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2007 | 347 | 0.060 |
Why?
|
Activating Transcription Factor 1 | 2 | 1995 | 9 | 0.060 |
Why?
|
Fetus | 2 | 2021 | 698 | 0.060 |
Why?
|
Receptors, Immunologic | 1 | 2006 | 198 | 0.060 |
Why?
|
Glomerular Filtration Rate | 2 | 2020 | 605 | 0.060 |
Why?
|
Kidney Tubules, Proximal | 1 | 2005 | 113 | 0.060 |
Why?
|
Interleukin-10 | 1 | 2006 | 293 | 0.060 |
Why?
|
Fasting | 1 | 2005 | 242 | 0.060 |
Why?
|
Olfactory Mucosa | 1 | 2004 | 60 | 0.060 |
Why?
|
Neurons, Afferent | 1 | 2004 | 85 | 0.060 |
Why?
|
Anthracenes | 1 | 2003 | 27 | 0.050 |
Why?
|
Cell Hypoxia | 2 | 2017 | 221 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2018 | 2764 | 0.050 |
Why?
|
Graft Occlusion, Vascular | 1 | 2003 | 35 | 0.050 |
Why?
|
Sucrose | 1 | 2023 | 92 | 0.050 |
Why?
|
Rats, Zucker | 2 | 2017 | 27 | 0.050 |
Why?
|
Glucose Oxidase | 1 | 2003 | 18 | 0.050 |
Why?
|
Protein Isoforms | 1 | 2004 | 337 | 0.050 |
Why?
|
Arteries | 2 | 2016 | 246 | 0.050 |
Why?
|
Tyrosine | 1 | 2004 | 210 | 0.050 |
Why?
|
Bromocriptine | 1 | 2022 | 26 | 0.050 |
Why?
|
Up-Regulation | 2 | 2010 | 802 | 0.050 |
Why?
|
Lipid Metabolism | 2 | 2016 | 441 | 0.050 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2003 | 82 | 0.050 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2003 | 68 | 0.050 |
Why?
|
Vitamin E | 1 | 2003 | 110 | 0.050 |
Why?
|
Adult Children | 1 | 2022 | 21 | 0.050 |
Why?
|
Regeneration | 1 | 2004 | 158 | 0.050 |
Why?
|
Diet, High-Fat | 1 | 2023 | 225 | 0.050 |
Why?
|
Computer Simulation | 2 | 2017 | 873 | 0.050 |
Why?
|
Ascorbic Acid | 1 | 2003 | 110 | 0.050 |
Why?
|
Fetal Heart | 1 | 2022 | 37 | 0.050 |
Why?
|
Carnitine | 1 | 2022 | 62 | 0.050 |
Why?
|
Immunohistochemistry | 2 | 2007 | 1624 | 0.050 |
Why?
|
Genetic Therapy | 1 | 2003 | 256 | 0.050 |
Why?
|
Circadian Rhythm | 2 | 2020 | 356 | 0.050 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 2 | 2001 | 192 | 0.050 |
Why?
|
Parathyroid Hormone | 2 | 1993 | 96 | 0.050 |
Why?
|
Mice, Obese | 1 | 2021 | 53 | 0.050 |
Why?
|
Base Sequence | 2 | 2009 | 2114 | 0.050 |
Why?
|
Aromatase Inhibitors | 1 | 2021 | 49 | 0.050 |
Why?
|
Arginine | 1 | 2003 | 236 | 0.050 |
Why?
|
Cell Death | 2 | 2016 | 322 | 0.050 |
Why?
|
Housing | 1 | 2022 | 114 | 0.050 |
Why?
|
Transcriptional Activation | 2 | 2003 | 337 | 0.050 |
Why?
|
Respiration | 1 | 2022 | 180 | 0.050 |
Why?
|
Cardiomegaly | 1 | 2022 | 158 | 0.050 |
Why?
|
Cross-Over Studies | 1 | 2022 | 439 | 0.050 |
Why?
|
Heart Function Tests | 2 | 2013 | 60 | 0.050 |
Why?
|
Risk Assessment | 1 | 2010 | 2958 | 0.050 |
Why?
|
Metabolic Networks and Pathways | 1 | 2022 | 167 | 0.050 |
Why?
|
Green Fluorescent Proteins | 2 | 2016 | 370 | 0.050 |
Why?
|
Medicare | 2 | 2022 | 661 | 0.040 |
Why?
|
Tamoxifen | 1 | 2021 | 190 | 0.040 |
Why?
|
Molecular Sequence Data | 2 | 2009 | 2783 | 0.040 |
Why?
|
Poverty | 1 | 2004 | 440 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 1 | 2001 | 396 | 0.040 |
Why?
|
Placental Insufficiency | 1 | 2021 | 102 | 0.040 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2001 | 270 | 0.040 |
Why?
|
Muscle Fibers, Skeletal | 1 | 2021 | 185 | 0.040 |
Why?
|
Myelin P2 Protein | 1 | 2000 | 2 | 0.040 |
Why?
|
Fatty Acid-Binding Protein 7 | 1 | 2000 | 3 | 0.040 |
Why?
|
Phenylbutazone | 1 | 2020 | 2 | 0.040 |
Why?
|
Tolbutamide | 1 | 2020 | 4 | 0.040 |
Why?
|
Bucladesine | 1 | 2000 | 24 | 0.040 |
Why?
|
Consensus Sequence | 1 | 2000 | 70 | 0.040 |
Why?
|
Oxazoles | 1 | 2020 | 29 | 0.040 |
Why?
|
Hypertrophy, Right Ventricular | 2 | 2013 | 141 | 0.040 |
Why?
|
Mutation | 2 | 2007 | 3338 | 0.040 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2000 | 152 | 0.040 |
Why?
|
Antigens, Differentiation | 1 | 2000 | 79 | 0.040 |
Why?
|
Linear Models | 2 | 2014 | 768 | 0.040 |
Why?
|
Pilot Projects | 2 | 2021 | 1360 | 0.040 |
Why?
|
Systole | 1 | 2020 | 176 | 0.040 |
Why?
|
Government Regulation | 1 | 2020 | 46 | 0.040 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2000 | 60 | 0.040 |
Why?
|
Cell Dedifferentiation | 1 | 2019 | 28 | 0.040 |
Why?
|
Physicians, Women | 1 | 2020 | 55 | 0.040 |
Why?
|
Proteins | 2 | 1996 | 906 | 0.040 |
Why?
|
Macrophages | 1 | 2006 | 1259 | 0.040 |
Why?
|
Muscle Proteins | 1 | 2001 | 210 | 0.040 |
Why?
|
Cell Transdifferentiation | 1 | 2019 | 31 | 0.040 |
Why?
|
Open Reading Frames | 1 | 2000 | 117 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2022 | 735 | 0.040 |
Why?
|
Sheep | 1 | 2021 | 761 | 0.040 |
Why?
|
MAP Kinase Kinase 6 | 1 | 1999 | 1 | 0.040 |
Why?
|
Sequence Alignment | 1 | 2000 | 323 | 0.040 |
Why?
|
Chromogranins | 1 | 1999 | 12 | 0.040 |
Why?
|
Glycine | 1 | 2020 | 152 | 0.040 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2020 | 172 | 0.040 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 172 | 0.040 |
Why?
|
PPAR alpha | 2 | 2010 | 52 | 0.040 |
Why?
|
Peer Group | 1 | 2020 | 200 | 0.040 |
Why?
|
Citric Acid Cycle | 1 | 2018 | 43 | 0.040 |
Why?
|
Pulmonary Circulation | 2 | 2013 | 407 | 0.040 |
Why?
|
Machine Learning | 1 | 2022 | 315 | 0.040 |
Why?
|
Hippocampus | 1 | 2003 | 690 | 0.040 |
Why?
|
Chromogranin A | 1 | 1999 | 39 | 0.040 |
Why?
|
Carotid Intima-Media Thickness | 1 | 2018 | 65 | 0.040 |
Why?
|
GTP Phosphohydrolases | 1 | 2018 | 65 | 0.040 |
Why?
|
Minority Groups | 1 | 2020 | 223 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-sis | 2 | 2010 | 33 | 0.040 |
Why?
|
Career Choice | 1 | 2020 | 178 | 0.040 |
Why?
|
Tandem Mass Spectrometry | 1 | 2021 | 410 | 0.040 |
Why?
|
Cloning, Molecular | 1 | 1999 | 522 | 0.040 |
Why?
|
Phenylephrine | 1 | 2018 | 71 | 0.040 |
Why?
|
Diet, Western | 1 | 2018 | 66 | 0.040 |
Why?
|
Hematocrit | 1 | 2018 | 86 | 0.040 |
Why?
|
Caspase 1 | 1 | 2018 | 140 | 0.040 |
Why?
|
Coronary Vessels | 1 | 2020 | 234 | 0.040 |
Why?
|
Flow Cytometry | 1 | 2001 | 1075 | 0.040 |
Why?
|
Universities | 1 | 2020 | 338 | 0.040 |
Why?
|
Antioxidants | 1 | 2001 | 529 | 0.040 |
Why?
|
Social Media | 1 | 2020 | 131 | 0.040 |
Why?
|
Cell Membrane | 3 | 2004 | 670 | 0.040 |
Why?
|
NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2018 | 144 | 0.040 |
Why?
|
Occupational Exposure | 1 | 2020 | 255 | 0.040 |
Why?
|
Adenosine Triphosphate | 2 | 2017 | 428 | 0.040 |
Why?
|
Risk | 1 | 2020 | 810 | 0.040 |
Why?
|
Postmenopause | 1 | 2019 | 301 | 0.030 |
Why?
|
Extracellular Matrix | 2 | 2013 | 436 | 0.030 |
Why?
|
Insulin Glargine | 1 | 2017 | 72 | 0.030 |
Why?
|
Magnetic Resonance Angiography | 1 | 2018 | 221 | 0.030 |
Why?
|
Binding Sites | 1 | 2000 | 1166 | 0.030 |
Why?
|
Nutritional Status | 1 | 2019 | 286 | 0.030 |
Why?
|
Social Support | 1 | 2020 | 528 | 0.030 |
Why?
|
Administration, Intravenous | 1 | 2017 | 122 | 0.030 |
Why?
|
Societies, Medical | 1 | 2020 | 655 | 0.030 |
Why?
|
Phosphorus Radioisotopes | 2 | 1993 | 27 | 0.030 |
Why?
|
Interleukin-1beta | 1 | 2018 | 368 | 0.030 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 1996 | 41 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 1998 | 845 | 0.030 |
Why?
|
Estradiol | 1 | 2019 | 450 | 0.030 |
Why?
|
Placenta | 1 | 2021 | 628 | 0.030 |
Why?
|
Carrier Proteins | 1 | 2000 | 694 | 0.030 |
Why?
|
Cohort Studies | 2 | 2020 | 4883 | 0.030 |
Why?
|
Collagen | 2 | 2009 | 414 | 0.030 |
Why?
|
Nitrendipine | 2 | 1993 | 13 | 0.030 |
Why?
|
Myocardial Ischemia | 1 | 2017 | 239 | 0.030 |
Why?
|
Heart Rate | 3 | 2009 | 710 | 0.030 |
Why?
|
Cytoplasm | 1 | 2016 | 255 | 0.030 |
Why?
|
Protein Phosphatase 2 | 1 | 1995 | 30 | 0.030 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 334 | 0.030 |
Why?
|
ras Guanine Nucleotide Exchange Factors | 1 | 1995 | 8 | 0.030 |
Why?
|
Coronavirus Infections | 1 | 2020 | 326 | 0.030 |
Why?
|
Absorptiometry, Photon | 1 | 2016 | 224 | 0.030 |
Why?
|
Lovastatin | 1 | 1995 | 26 | 0.030 |
Why?
|
Glycogen | 1 | 1995 | 51 | 0.030 |
Why?
|
Peptide Mapping | 1 | 1994 | 60 | 0.030 |
Why?
|
Cystatin C | 1 | 2014 | 62 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1999 | 1836 | 0.030 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 1995 | 55 | 0.030 |
Why?
|
Phosphorus | 1 | 2014 | 81 | 0.030 |
Why?
|
Interleukin-6 | 2 | 2009 | 673 | 0.030 |
Why?
|
Stress, Mechanical | 1 | 2016 | 445 | 0.030 |
Why?
|
Fatty Acid Synthases | 2 | 2006 | 23 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2013 | 26 | 0.030 |
Why?
|
Rats, Inbred Strains | 2 | 1991 | 360 | 0.030 |
Why?
|
Lipolysis | 1 | 2013 | 39 | 0.030 |
Why?
|
Delivery, Obstetric | 1 | 2014 | 118 | 0.030 |
Why?
|
Biomechanical Phenomena | 1 | 2016 | 669 | 0.030 |
Why?
|
Protein Stability | 1 | 2013 | 156 | 0.030 |
Why?
|
Carbon Radioisotopes | 1 | 1993 | 36 | 0.030 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 2013 | 56 | 0.030 |
Why?
|
Acyl Coenzyme A | 1 | 2013 | 30 | 0.030 |
Why?
|
Body Weight | 1 | 2017 | 868 | 0.030 |
Why?
|
Adolescent Health Services | 1 | 2013 | 68 | 0.030 |
Why?
|
Registries | 1 | 2020 | 1764 | 0.030 |
Why?
|
Reference Values | 2 | 2007 | 739 | 0.030 |
Why?
|
Cardiolipins | 1 | 2013 | 70 | 0.030 |
Why?
|
Colorado | 2 | 2017 | 4090 | 0.030 |
Why?
|
Physicians | 1 | 2020 | 765 | 0.020 |
Why?
|
Pandemics | 1 | 2020 | 1310 | 0.020 |
Why?
|
Immunoblotting | 2 | 2007 | 282 | 0.020 |
Why?
|
Optic Chiasm | 1 | 1992 | 18 | 0.020 |
Why?
|
Nerve Compression Syndromes | 1 | 1992 | 24 | 0.020 |
Why?
|
Premenopause | 2 | 2003 | 105 | 0.020 |
Why?
|
Mice, Inbred NOD | 2 | 2004 | 552 | 0.020 |
Why?
|
Muscle Strength | 1 | 2014 | 271 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 1995 | 1228 | 0.020 |
Why?
|
Thyrotropin | 1 | 1992 | 100 | 0.020 |
Why?
|
Hypothyroidism | 1 | 1992 | 65 | 0.020 |
Why?
|
Heart Ventricles | 1 | 2016 | 723 | 0.020 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 1992 | 51 | 0.020 |
Why?
|
Potassium | 1 | 1991 | 127 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2014 | 1422 | 0.020 |
Why?
|
Headache | 1 | 1992 | 132 | 0.020 |
Why?
|
Protein Binding | 1 | 2016 | 1888 | 0.020 |
Why?
|
Inflammation | 3 | 2009 | 2464 | 0.020 |
Why?
|
Vision Disorders | 1 | 1992 | 127 | 0.020 |
Why?
|
Pituitary Neoplasms | 1 | 1992 | 156 | 0.020 |
Why?
|
Child Development | 1 | 2014 | 384 | 0.020 |
Why?
|
Adenoma | 1 | 1992 | 187 | 0.020 |
Why?
|
Cytosol | 1 | 2010 | 201 | 0.020 |
Why?
|
CCN Intercellular Signaling Proteins | 1 | 2009 | 5 | 0.020 |
Why?
|
Body Fat Distribution | 1 | 2009 | 46 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2011 | 534 | 0.020 |
Why?
|
Plethysmography | 1 | 2009 | 103 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2011 | 341 | 0.020 |
Why?
|
Placebo Effect | 1 | 2009 | 52 | 0.020 |
Why?
|
Swimming | 1 | 2009 | 44 | 0.020 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2009 | 64 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 2020 | 4595 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2009 | 249 | 0.020 |
Why?
|
Hormones | 1 | 2009 | 132 | 0.020 |
Why?
|
Puberty | 1 | 2009 | 135 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2016 | 4392 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 1992 | 1331 | 0.020 |
Why?
|
Myoglobin | 1 | 2007 | 14 | 0.020 |
Why?
|
Betacellulin | 1 | 2007 | 6 | 0.020 |
Why?
|
Saliva | 1 | 2009 | 188 | 0.020 |
Why?
|
Protein Transport | 1 | 2009 | 391 | 0.020 |
Why?
|
Fenofibrate | 1 | 2007 | 24 | 0.020 |
Why?
|
Caspase 9 | 1 | 2007 | 48 | 0.020 |
Why?
|
In Situ Nick-End Labeling | 1 | 2007 | 119 | 0.020 |
Why?
|
Hypolipidemic Agents | 1 | 2007 | 86 | 0.020 |
Why?
|
Adenylyl Cyclase Inhibitors | 1 | 2006 | 5 | 0.020 |
Why?
|
Running | 1 | 2009 | 207 | 0.020 |
Why?
|
Elastin | 1 | 2006 | 78 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2009 | 6306 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2006 | 63 | 0.020 |
Why?
|
Adenoviridae | 1 | 2007 | 184 | 0.020 |
Why?
|
Intracellular Membranes | 1 | 2006 | 73 | 0.020 |
Why?
|
Cysteine Proteinase Inhibitors | 1 | 2006 | 45 | 0.020 |
Why?
|
Proteasome Inhibitors | 1 | 2006 | 41 | 0.020 |
Why?
|
Heme Oxygenase-1 | 1 | 2006 | 51 | 0.020 |
Why?
|
Haptoglobins | 1 | 2006 | 47 | 0.020 |
Why?
|
Receptors, IgG | 1 | 2006 | 67 | 0.020 |
Why?
|
Ubiquitin | 1 | 2006 | 57 | 0.020 |
Why?
|
Caspases | 1 | 2007 | 243 | 0.020 |
Why?
|
Cadaver | 1 | 2007 | 298 | 0.020 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2006 | 109 | 0.020 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2006 | 84 | 0.020 |
Why?
|
RNA Stability | 1 | 2006 | 90 | 0.020 |
Why?
|
Macaca mulatta | 1 | 2006 | 131 | 0.020 |
Why?
|
Interleukin-8 | 1 | 2006 | 229 | 0.020 |
Why?
|
Acetylcysteine | 1 | 2006 | 141 | 0.020 |
Why?
|
NF-kappa B | 1 | 2009 | 636 | 0.020 |
Why?
|
Mice, Inbred Strains | 1 | 2005 | 398 | 0.010 |
Why?
|
Cholesterol, HDL | 1 | 2005 | 184 | 0.010 |
Why?
|
Antibodies | 1 | 2006 | 365 | 0.010 |
Why?
|
Mice, Congenic | 1 | 2004 | 21 | 0.010 |
Why?
|
Lung | 1 | 2016 | 3521 | 0.010 |
Why?
|
Receptors, Odorant | 1 | 2004 | 35 | 0.010 |
Why?
|
Patient Selection | 1 | 2007 | 629 | 0.010 |
Why?
|
Molecular Mimicry | 1 | 2003 | 35 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 924 | 0.010 |
Why?
|
Membrane Potentials | 1 | 2004 | 247 | 0.010 |
Why?
|
Smell | 1 | 2004 | 111 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 2006 | 813 | 0.010 |
Why?
|
Genetic Vectors | 1 | 2004 | 287 | 0.010 |
Why?
|
Imidazoles | 1 | 2003 | 203 | 0.010 |
Why?
|
Serum Globulins | 1 | 2002 | 4 | 0.010 |
Why?
|
Data Collection | 1 | 2005 | 618 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2009 | 932 | 0.010 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 2002 | 75 | 0.010 |
Why?
|
Protein Prenylation | 1 | 2001 | 19 | 0.010 |
Why?
|
Infant | 1 | 2014 | 7943 | 0.010 |
Why?
|
Fibrinogen | 1 | 2002 | 143 | 0.010 |
Why?
|
Glucose Transporter Type 4 | 1 | 2001 | 36 | 0.010 |
Why?
|
Administration, Oral | 1 | 2003 | 725 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2004 | 1080 | 0.010 |
Why?
|
Tissue Plasminogen Activator | 1 | 2002 | 204 | 0.010 |
Why?
|
Pyridines | 1 | 2003 | 419 | 0.010 |
Why?
|
Densitometry | 1 | 1998 | 29 | 0.010 |
Why?
|
Autonomic Nervous System | 1 | 1998 | 66 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 1986 | 1356 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2003 | 650 | 0.010 |
Why?
|
Lactic Acid | 1 | 1998 | 272 | 0.010 |
Why?
|
Immunosorbent Techniques | 1 | 1996 | 17 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 1996 | 43 | 0.010 |
Why?
|
ras GTPase-Activating Proteins | 1 | 1996 | 13 | 0.010 |
Why?
|
Smoking | 1 | 2003 | 1382 | 0.010 |
Why?
|
Chromones | 1 | 1996 | 35 | 0.010 |
Why?
|
Guanosine Triphosphate | 1 | 1996 | 85 | 0.010 |
Why?
|
CHO Cells | 1 | 1996 | 137 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 1996 | 113 | 0.010 |
Why?
|
GTPase-Activating Proteins | 1 | 1996 | 72 | 0.010 |
Why?
|
Cricetinae | 1 | 1996 | 252 | 0.010 |
Why?
|
Morpholines | 1 | 1996 | 102 | 0.010 |
Why?
|
Primary Health Care | 1 | 2004 | 1502 | 0.010 |
Why?
|
Thapsigargin | 1 | 1993 | 18 | 0.010 |
Why?
|
Thionucleotides | 1 | 1993 | 34 | 0.010 |
Why?
|
Calcium-Transporting ATPases | 1 | 1993 | 34 | 0.010 |
Why?
|
Terpenes | 1 | 1993 | 21 | 0.010 |
Why?
|
Neoplasms | 1 | 1986 | 2086 | 0.010 |
Why?
|
Biological Transport | 1 | 1993 | 374 | 0.010 |
Why?
|
Disulfiram | 1 | 1986 | 13 | 0.000 |
Why?
|
Drug Evaluation | 1 | 1986 | 77 | 0.000 |
Why?
|
Drug Evaluation, Preclinical | 1 | 1986 | 159 | 0.000 |
Why?
|
Cisplatin | 1 | 1986 | 262 | 0.000 |
Why?
|